Zynerba Pharmaceuticals, Inc. financial data

Industry
Pharmaceutical Preparations
Location
80 W. Lancaster Avenue, Suite 300, Devon, PA
State of incorporation
DE
Fiscal year end
December 31
Former names
Zynerba Pharmeceuticals, Inc. (to 6/30/2015)
Latest financial report
10-Q - Q2 2023 - Aug 14, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 510 % -34.8%
Debt-to-equity 24 % +60.8%
Return On Equity -90 % -62.2%
Return On Assets -72.6 % -50.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 53.9M shares +17.9%
Common Stock, Shares, Outstanding 53.9M shares +22.8%
Common Stock, Value, Issued 53.9K USD +22.8%
Weighted Average Number of Shares Outstanding, Basic 50.2M shares +21.1%
Weighted Average Number of Shares Outstanding, Diluted 50.2M shares +21.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 24.8M USD +12.7%
General and Administrative Expense 14M USD -7.44%
Operating Income (Loss) -38.8M USD -4.49%
Nonoperating Income (Expense) 1.2M USD
Net Income (Loss) Attributable to Parent -37.6M USD +0.42%
Earnings Per Share, Basic -0.79 USD/shares +16.8%
Earnings Per Share, Diluted -0.79 USD/shares +16.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 36M USD -42.4%
Other Assets, Current 629K USD -6.42%
Assets, Current 39.3M USD -40.2%
Property, Plant and Equipment, Net 395K USD +22.4%
Operating Lease, Right-of-Use Asset 219K USD -51.5%
Assets 40.5M USD -39.6%
Accounts Payable, Current 2.48M USD +48%
Accrued Liabilities, Current 8.76M USD +14.6%
Liabilities, Current 11.5M USD +20.2%
Operating Lease, Liability, Noncurrent 60K USD -79.7%
Liabilities 11.5M USD +17.3%
Retained Earnings (Accumulated Deficit) -295M USD -14.6%
Stockholders' Equity Attributable to Parent 29M USD -49.3%
Liabilities and Equity 40.5M USD -39.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.88M USD -4028%
Net Cash Provided by (Used in) Financing Activities 1.73M USD -0.67%
Net Cash Provided by (Used in) Investing Activities -89.6K USD -73.5%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 53.9M shares +22.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.24M USD -430%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 36M USD -42.4%
Operating Lease, Liability 218K USD -51.5%
Depreciation 51.6K USD -14.9%
Payments to Acquire Property, Plant, and Equipment 89.6K USD +73.5%
Lessee, Operating Lease, Liability, to be Paid 220K USD -52.2%
Property, Plant and Equipment, Gross 1.58M USD +22.9%
Operating Lease, Liability, Current 218K USD +2.79%
Lessee, Operating Lease, Liability, to be Paid, Year Two 100K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 100K USD -58.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.03 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.51K USD -78.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Operating Lease, Payments 85.5K USD +10.1%
Additional Paid in Capital 324M USD +2.97%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%